<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        178-212-03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2003
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SNAFI 20MG TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TADALAFIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        88.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G04BE08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Snafi</strong> is a treatment for adult men with erectile dysfunction. This is when a man cannot get, or keep a hard, erect penis suitable for sexual activity. <strong>Snafi</strong> has been shown to significantly improve the ability of obtaining a hard erect penis suitable for sexual activity.</p><p>&nbsp;</p><p><strong>Snafi</strong> contains the active substance tadalafil which belongs to a group of medicines called phosphodiesterase type 5 inhibitors. Following sexual stimulation <strong>Snafi</strong> works by helping the blood vessels in your penis to relax, allowing the flow of blood into your penis. The result of this is improved erectile function. <strong>Snafi</strong> will not help you if you do not have erectile dysfunction.</p><p>&nbsp;</p><p>It is important to note that <strong>Snafi</strong> does not work if there is no sexual stimulation. You and your partner will need to engage in foreplay, just as you would if you were not taking a medicine for erectile dysfunction.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Snafi</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to tadalafil or any of the other ingredients of <strong>Snafi </strong>(listed in section 6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking any form of organic nitrate or nitric oxide donors such as amyl nitrite. This is a group of medicines (&ldquo;nitrates&rdquo;) used in the treatment of angina pectoris (&ldquo;chest pain&rdquo;). <strong>Snafi</strong> has been shown to increase the effects of these medicines. If you are taking any form of nitrate or are unsure tell your doctor.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have serious heart disease or have had a recent heart attack within the last 90 days.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have had a recent stroke within the last 6 months.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have low blood pressure or uncontrolled high blood pressure.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have ever had loss of vision because of non-arteritic anterior ischemic optic neuropathy (NAION), a condition described as &ldquo;stroke of the eye&rdquo;.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking riociguat. This drug is used to treat pulmonary arterial hypertension (i.e., high blood pressure in the lungs) and chronic thromboembolic pulmonary hypertension (i.e., high blood pressure in the lungs secondary to blood clots). PDE5 inhibitors, such as <strong>Snafi</strong>, have been shown to increase the hypotensive effects of this medicine. If you are taking riociguat or are unsure tell your doctor.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor before taking <strong>Snafi</strong>.</p><p>Be aware that sexual activity carries a possible risk to patients with heart disease because it puts an extra strain on your heart. If you have a heart problem you should tell your doctor.</p><p>&nbsp;</p><p>Before taking the tablets, tell your doctor if:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have sickle cell anaemia (an abnormality of red blood cells).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have multiple myeloma (cancer of the bone marrow).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have leukaemia (cancer of the blood cells).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have any deformation of your penis.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have a serious liver problem.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have a severe kidney problem</p><p>&nbsp;</p><p>It is not known if <strong>Snafi</strong> is effective in patients who have had:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pelvic surgery.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Removal of all or part of the prostate gland in which nerves of the prostate are cut (radical non-nerve-sparing prostatectomy).</p><p>&nbsp;</p><p>If you experience sudden decrease or loss of vision, stop taking <strong>Snafi</strong> and contact your doctor immediately.</p><p>&nbsp;</p><p>Decreased or sudden hearing loss has been noted in some patients taking tadalafil. Although it is not known if the event is directly related to tadalafil, if you experience decreased or sudden hearing loss, stop taking Tadalafil and contact your doctor immediately.</p><p>&nbsp;</p><p><strong>Snafi</strong> is not intended for use by women.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p><strong>Snafi</strong> is not intended for use by children and adolescents under the age of 18.</p><p>&nbsp;</p><p><strong>Other medicines and Snafi</strong></p><p>Please tell your doctor if you are taking, have recently taken or might take any other medicines. Do not take <strong>Snafi</strong> if you are already taking nitrates.</p><p>&nbsp;</p><p>Some medicines may be affected by <strong>Snafi</strong> or they may affect how well <strong>Snafi</strong> will work. Tell your doctor or pharmacist if you are already taking:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An alpha blocker (used to treat high blood pressure or urinary symptoms associated with benign prostatic hyperplasia).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other medicines to treat high blood pressure.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Riociguat.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A 5- alpha reductase inhibitor (used to treat benign prostatic hyperplasia).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines such as ketoconazole tablets (to treat fungal infections) and protease inhibitors for treatment of AIDS or HIV infection.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Phenobarbital, phenytoin and carbamazepine (anticonvulsant medicines).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rifampicin, erythromycin, clarithromycin or itraconazole.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other treatments for erectile dysfunction.<strong> </strong></p><p><strong>&nbsp;</strong></p><p><strong>Snafi with drink and alcohol</strong></p><p>Information on the effect of alcohol is in section 3. Grapefruit juice may affect how well <strong>Snafi </strong>will work and should be taken with caution. Talk to your doctor for further information.</p><p><strong>&nbsp;</strong></p><p><strong>Fertility</strong></p><p>When dogs were treated there was reduced sperm development in the testes. A reduction in sperm was seen in some men. These effects are unlikely to lead to a lack of fertility.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Some men taking <strong>Snafi</strong> in clinical studies have reported dizziness. Check carefully how you react to the medicines before driving or using any machines.</p><p>&nbsp;</p><p><strong>Snafi contains lactose:</strong></p><p>If you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take <strong>Snafi</strong> exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>Snafi</strong> tablets are for oral use in men only. Swallow the tablet whole with some water. The tablets can be taken with or without food.</p><p>&nbsp;</p><p>The recommended starting dose is 10 mg before sexual activity. However, you have been given the dose of one 20 mg tablet as your doctor has decided that the recommended dose of 10 mg is too weak.</p><p>&nbsp;</p><p>You may take a <strong>Snafi</strong> tablet at least 30 minutes before sexual activity. <strong>Snafi</strong> may still be effective up to 36 hours after taking the tablet.</p><p>&nbsp;</p><p>Do not take <strong>Snafi</strong> more than once a day. <strong>Snafi</strong> 20 mg is intended for use prior to anticipated sexual activity and is not recommended for continuous daily use.</p><p>&nbsp;</p><p>It is important to note that <strong>Snafi</strong> does not work if there is no sexual stimulation. You and your partner will need to engage in foreplay, just as you would if you were not taking a medicine for erectile dysfunction.</p><p>&nbsp;</p><p>Drinking alcohol may affect your ability to get an erection. Drinking alcohol may temporarily lower your blood pressure. If you have taken or are planning to take <strong>Snafi</strong>, avoid excessive drinking (blood alcohol level of 0.08% or greater), since this may increase the risk of dizziness when standing up.</p><p>&nbsp;</p><p><strong>If you take more Snafi than you should</strong></p><p>Contact your doctor. You may experience side effects described in section 4.</p><p>&nbsp;</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, <strong>Snafi</strong> can cause side effects, although not everybody gets them. These effects are normally mild to moderate in nature.</p><p>&nbsp;</p><p><strong>If you experience any of the following side effects stop using the medicine and seek medical help immediately:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions including rashes (frequency uncommon).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest pain - do not use nitrates but seek immediate medical assistance (frequency uncommon).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Priapism, prolonged and possibly painful erection after taking <strong>Snafi</strong> (frequency rare). If you have such an erection, which lasts continuously for more than 4 hours you should contact a doctor immediately.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden loss of vision (frequency rare).</p><p>&nbsp;</p><p>Other side effects have been reported.</p><p><strong>Common</strong> (seen in 1 to 10 in every 100 patients)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache, back pain, muscle aches, pain in arms and legs, facial flushing, nasal congestion, and indigestion.</p><p>&nbsp;</p><p><strong>Uncommon</strong> (seen in 1 to 10 in every 1,000 patients)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness, stomach ache, feeling sick, being sick (vomiting), reflux, blurred vision, eye pain, difficulty in breathing, presence of blood in urine, prolonged erection, pounding heartbeat sensation, a fast heart rate, high blood pressure, low blood pressure, nose bleeds and ringing in the ears, swelling of the hands, feet or ankles and feeling tired.</p><p>&nbsp;</p><p><strong>Rare</strong> (seen in 1 to 10 in every 10,000 patients)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fainting, seizures and passing memory loss, swelling of the eyelids, red eyes, sudden decrease or loss of hearing and hives (itchy red welts on the surface of the skin), penile bleeding, presence of blood in semen and increased sweating.</p><p>&nbsp;</p><p>Heart attack and stroke have also been reported rarely in men taking <strong>Snafi</strong>. Most of these men had known heart problems before taking this medicine.</p><p>&nbsp;</p><p>Partial, temporary, or permanent decrease or loss of vision in one or both eyes has been rarely reported.</p><p>&nbsp;</p><p><strong>Some additional rare side effects</strong> have been reported in men taking <strong>Snafi</strong> that were not seen in clinical trials. These include:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Migraine, swelling of the face, serious allergic reaction which causes swelling of the face or throat, serious skin rashes, some disorders affecting blood flow to the eyes, irregular heartbeats, angina and sudden cardiac death.</p><p>&nbsp;</p><p>The side effects dizziness has been reported more frequently in men over 75 years of age taking <strong>Snafi</strong>. Diarrhoea has been reported more frequently in men over 65 years of age taking <strong>Snafi</strong>.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via The National Pharmacovigilance and Drug Safety Centre (NPC). By reporting side effects, you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use <strong>Snafi</strong> after the expiry date stated on the carton and blister after &lsquo;EXP&rsquo;. The expiry date refers to the last day of that month.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package in order to protect from moisture. Do not store above 30&deg;C.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The <strong>active</strong> substance is tadalafil.</p><p>Each film-coated tablet of Snafi 20 mg contains 20 mg of tadalafil.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The <strong>other ingredients</strong> are:</p><p>Lactose NF Fast Flow, Avicel PH 101, Croscarmellose sodium type A, Sheffcel 60hd3, and Sodium Lauryl Sulphate.</p><p>Extra Granular Material:</p><p>Avicel PH 102, Croscarmellose sodium type A, Colloidal Silicon Dioxide, and Magnesium Stearate.</p><p>Coating:</p><p>Opadry II 32F220050 Yellow, and Purified Water BP.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Snafi 20 mg tablet is a yellow-colored, almond-shaped, biconvex, film-coated tablet, engraved with “T20” on one side and plain on the other side.
Each pack of Snafi 20 mg contains 2, 4, 6 or 12 film-coated tablets.
Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>SPIMACO</strong></p><p>Al<strong>-</strong>Qassim Pharmaceutical Plant</p><p>Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                September 2022.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>سنافي</strong> هو علاج للرجال البالغين الذين يعانون من ضعف الإنتصاب. ويحدث ذلك عندما يعجز الرجل عن جعل &ndash; أو الإبقاء على &ndash; القضيب صلباً ومنتصباً بما يلائم النشاط الجنسي. يؤدي <strong>سنافي</strong> إلى تحسن كبير في القدرة علي الحصول علي قضيب منتصب صلب مناسب للنشاط الجنسي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي <strong>سنافي</strong> علي المادة الفعالة (تادالافيل) و التي تنتمي لمجموعة من الأدوية تسمى مثبطات إنزيم فوسفو داي إستريز نوع 5. ويعمل <strong>سنافي</strong> - عقب الإثارة الجنسية - علي المساعدة علي ارتخاء الأوعية الدموية الموجودة في القضيب، بما يسمح بتدفق الدم إلي القضيب. وينتج عن ذلك تحسن وظيفة الإنتصاب. لن يساعدك سنافي إن لم تكن مصاباً بضعف الإنتصاب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من المهم أن تعلم أن <strong>سنافي</strong> لا يعمل إن لم تكن هناك إثارة جنسية. لذا ستكون أنت وشريكتك بحاجة إلى مداعبة ما قبل الجماع، تماماً كما تفعل إن لم تكن تتناول دواءً لعلاج ضعف الإنتصاب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>امتنع عن تناول سنافي في الحالات الآتية:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بفرط الحساسية لمادة تادالافيل أو أي من المكونات الأخرى لـ <strong>سنافي</strong> (المذكورة فى فقرة 6).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أياً من أنواع النيترات العضوي أو مانحين أكسيد النيتريك مثل أميل نيتريت. وهي مجموعة من الأدوية تسمى &quot;نيترات&quot; وتستخدم في علاج الذبحة الصدرية (&quot;ألم الصدر&quot;). فقد تبين أن <strong>سنافي</strong> يزيد من تأثير تلك الأدوية. إن كنت تتناول أياً من أشكال النيترات أو كنت غير واثق، فبادر باستشارة طبيبك المعالج.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بمرض قلبي خطير أو أصابتك مؤخراً أزمة قلبية خلال الـ 90 يوم السابقين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت مؤخراً بسكتة دماغية خلال الـ 6 أشهر السابقة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من انخفاض ضغط الدم أو ارتفاع ضغط الدم غير المنضبط.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا سبقت لك الإصابة بفقد البصر بسبب اعتلال عصبي بصري إقفاري أمامي غير ناتج عن التهاب شرياني (NAION)، وهي حالة توصف بـ &quot;سكتة العين&quot;.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول ريوسيجوات. يستخدم هذا الدواء لعلاج ارتفاع ضغط الدم الشرياني الرئوي (أي ارتفاع ضغط الدم في الرئتين) وارتفاع ضغط الدم الرئوي الانسدادي التجلطي المزمن (أي ارتفاع ضغط الدم في الرئتين الثانوي لتجلط الدم). وقد ثبت زيادة مثبطات إنزيم فوسفو داي إستريز نوع 5، مثل <strong>سنافي</strong>، آثار انخفاض ضغط الدم لهذا الدواء. إذا كنت تتناول ريوسيجوات أو غير متأكد أخبر طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك قبل تناول<strong> سنافي.</strong></p><p dir="RTL">عليك أن تدرك أن النشاط الجنسي ينطوي على خطورة محتملة بالنسبة لمرضى القلب لأنه يضع جهداً إضافياً علي القلب. إذا كنت تعاني من مشكلة قلبية، فإنه ينبغي لك أن تخبر طبيبك المعالج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك المعالج قبل أن تبدأ في تناول الدواء:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بأنيميا الخلايا المنجلية (وهو مرض يصيب خلايا الدم الحمراء).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بالورم النخاعي المتعدد (وهو سرطان بنخاع العظام).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بلوكيميا (وهو سرطان بخلايا الدم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بأية تشوهات في القضيب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلة خطيرة بالكبد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ذا كنت تعاني من مشكلة خطيرة بالكلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ليس من المعلوم ما إذا كان <strong>سنافي</strong>&nbsp; فعالاً بالنسبة للمرضى الذين سبق أن:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خضعوا لعملية جراحية بمنطقة الحوض.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خضعوا لعملية استئصال كلي أو جزئي للبروستاتا دون المحافظة على الأعصاب (استئصال البروستاتا الجذري بدون تجنيب الأعصاب).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تعرضت لانخفاض مفاجئ في قوة الإبصار أو لفقد البصر، فعليك التوقف عن تناول أقراص <strong>سنافي</strong> والتواصل مباشرة مع طبيبك المعالج.</p><p dir="RTL">قد تم رصد انخفاض أو فقدان السمع المفاجئ في بعض المرضى عند تناول أقراص <strong>سنافي</strong>. على الرغم من أنه من غير المعروف ما إذا كان الحدث مرتبطاً بشكل مباشر بسنافي، إذا كنت تعاني من ضعف فى السمع أو فقدان مفاجئ للسمع، فتوقف عن تناول أقراص سنافى وتواصل مع طبيبك المعالج فوراً. &nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>سنافي</strong> غير مخصص للتناول من قبل النساء</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">أقراص <strong>سنافي</strong> ليست مخصصة للتناول من قبل الأطفال والمراهقين الذين تقل أعمارهم عن 18 عاما.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى و</strong><strong>سنافي</strong></p><p dir="RTL">يرجى أن تخبر طبيبك المعالج إن كنت تتناول حالياً، تناولت مؤخراً أو فد تتناول أية أدوية أخرى. لا تتناول <strong>سنافي</strong> إذا كنت تتناول أدوية النيترات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تتأثر بعض الأدوية بـ <strong>سنافي</strong> أو أنها قد تؤثر على طريقة عمل <strong>سنافي</strong>. أخبر طبيبك أو الصيدلي إذا كنت تتناول بالفعل:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مانع ألفا (التي تستخدم لعلاج ارتفاع ضغط الدم أو الأعراض البولية المرتبطة بتضخم البروستاتا الحميد).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ادوية أخرى لعلاج ارتفاع ضغط الدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريوسيجوات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مانع مختزل 5- ألفا (الذي يستخدم لعلاج تضخم البروستاتا).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية مثل أقراص كيتوكونازول (لعلاج العدوي الفطرية) ومثبطات الأنزيم البروتيني لعلاج عدوي الإيدز أو فيروس نقص المناعة البشرية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينوباربيتال، فينيتوين وكاربامازيبين (أدوية مضادة للتشنجات).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين، إريثروميسين، كلاريثروميسين أو إيتراكونازول.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العلاجات الأخرى لضعف الانتصاب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>سنافي مع الطعام والشراب</strong></p><p dir="RTL">المعلومات حول تأثير الكحول في الفقرة 3. قد يؤثر عصير الجريب فروت على طريقة عمل <strong>سنافي</strong> وينبغي أن يؤخذ بحذر. تحدث إلى طبيبك للحصول على مزيد من المعلومات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الخصوبة</strong></p><p dir="RTL">عندما تم تجربته في علاج الكلاب كان هناك انخفاض في تطوير الحيوانات المنوية في الخصيتين. شوهد انخفاض في الحيوانات المنوية عند بعض الرجال. من غير المرجح أن تؤدي هذه التأثيرات إلى نقص الخصوبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قيادة المركبات وتشغيل الآلات </strong></p><p dir="RTL">قام بعض الرجال الذين تناولوا <strong>سنافي</strong> من خلال دراسات إكلينيكية بالإبلاغ عن حدوث دوار. ينبغي أن تتحقق وبحرص من كيفية تفاعلك مع الأدوية قبل أن تقدم على القيادة أو تشغيل أية ماكينات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي سنافي على لاكتوز:</strong></p><p dir="RTL">فإذا كنت لا تستطيع تحمل بعض السكريات، فعليك التواصل مع طبيبك قبل أن تبدأ في تناول هذا المنتج الدوائي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائما على تناول <strong>سنافي</strong> كما ينصحك طبيبك. وينبغي عليك أن تراجع طبيبك أو الصيدلي الذي تتعامل معه إذا كنت غير واثق من طريقة تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أقراص <strong>سنافي</strong> معدة للتناول عن طريق الفم من قبل الرجال فقط. قم بإبتلاع القرص كاملاً مع الماء. يمكنك تناول أقراص <strong>سنافي</strong> مع الطعام أو بدونه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة التي ينصح بتناولها في بداية العلاج هي 10 ملجم يتم تناولها قبل الممارسة الجنسية. ومع ذلك، فقد تم اعطاؤك جرعة من قرص واحد 20 ملجم حيث قرر طبيبك أن الجرعة الموصي بها وهي 10 ملجم ضعيفة للغاية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكنك تناول قرص <strong>سنافي</strong> قبل الممارسة الجنسية بثلاثين دقيقة على الأقل. قد تمتد فعالية <strong>سنافي</strong> لمدة تصل إلى 36 ساعة بعد تناول القرص.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتناول <strong>سنافي</strong> أكثر من مرة واحدة يوميا. يستخدم <strong>سنافي</strong> 20 ملجم قبل النشاط الجنسي المتوقع ولا يوصى بالاستخدام اليومي المستمر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من المهم ملاحظة أن <strong>سنافي</strong> لا يعمل ما لم تحدث إثارة جنسية. لذا ستكون أنت وشريكتك بحاجة إلى الإنشغال بمداعبة ما قبل الجماع، تماماً كما تفعل إن لم تكن تتناول دواءً لعلاج ضعف الإنتصاب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يؤثر تناول المشروبات الكحولية على قدرتك على الإنتصاب. وقد يسبب تناول المشروبات الكحولية انخفاض ضغط الدم لديك على نحو مؤقت. إذا تناولت أقراص <strong>سنافي</strong> أو عزمت على تناولها، فعليك أن تتجنب الإفراط في الشراب (بمعنى أن يصل مستوى الكحول في الدم إلى 0.08 % أو أعلى)، فإن ذلك قد يزيد من احتمالية الشعور بالدوار عند الوقوف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت أكثر مما يجب من أقراص سنافي</strong></p><p dir="RTL">تواصل مع طبيبك، قد تتعرض لبعض الأعراض الجانبية الموصوفة في الفقرة رقم 4.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى بشأن تناول هذا الدواء، يمكنك سؤال طبيبك أو الصيدلي الذي تتعامل معه.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو شأن كافة الأدوية، يمكن أن تسبب أقراص <strong>سنافي</strong> أعراض جانبية، ولو أن تلك الأعراض لا تحدث لكل من يتناول الدواء. وعادة ما تكون تلك التأثيرات بسيطة إلى متوسطة الشدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كنت تواجه أي من الأعراض الجانبية التالية. توقف عن استخدام الدواء واطلب المساعدة الطبية على الفور:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود الفعل التحسسية بما في ذلك الطفح الجلدي (نسبة الحدوث: غير شائع).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر - لا تستخدم النيترات ولكن اطلب مساعدة طبية فورية (نسبة الحدوث: غير شائع).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانتصاب لفترات طويلة، وربما المؤلم بعد تناول <strong>سنافي</strong> (نسبة الحدوث: نادر). إذا كان لديك مثل هذا الإنتصاب، والذي يستمر لأكثر من 4 ساعات بشكل مستمر. يجب عليك الاتصال بالطبيب فورا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم الرؤية الفجائي (نادر الحصول).</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الإبلاغ عن أعراض جانبية أخرى:</p><p dir="RTL"><strong>شائعة</strong> (شوهد في 1 الي 10 من كل 100 مريض):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع، ألم الظهر، ألم في العضلات، وألم في الذراعين والساقين، واحمرار الوجه، واحتقان الانف، وعسر الهضم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong> (شوهد في 1 الي 10 من كل 1000 مريض):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة، وألم في المعدة، الشعور بالغثيان، القيء، الارتجاع، عدم وضوح الرؤية، وألم في العين، وصعوبة في التنفس، وجود دم في البول، الإحساس بزيادة في ضربات القلب، وسرعة دقات القلب، وارتفاع ضغط الدم، أو انخفاض ضغط الدم، ونزيف في الأنف وطنين في الأذنين، تورم في اليدين، أو القدمين أو الكاحلين والشعور بالتعب.</p><p dir="RTL"><strong>نادرة </strong>(شوهد في 1 الي 10 من كل 10000 مريض):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإغماء، والتشنجات، وفقدان الذاكرة، وتورم في الجفون واحمرار في العينين، وانخفاض مفاجئ أو فقدان السمع والشرى (بقع حمراء وحكة على سطح الجلد)، نزيف بالقضيب، وجود دم فى السائل المنوي وزيادة التعرق.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كما تم الإبلاغ عن النوبات القلبية والسكتة الدماغية بشكل نادر في الرجال الذين يتناولون <strong>سنافي</strong>. وكان معظم هؤلاء الرجال لديهم</p><p dir="RTL">مشاكل معروفة في القلب قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الإبلاغ عن نقصان أو فقدان البصر الجزئي المؤقت أو الدائم في إحدى أو كلتا العينين بشكل نادر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وقد تم الإبلاغ عن بعض <strong>الأعراض الجانبية الإضافية النادرة </strong>في الرجال الذين يتناولون <strong>سنافي</strong> التي لم تحدث في التجارب السريرية. وتشمل هذه:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع النصفي، وتورم في الوجه، تفاعلات الحساسية الخطيرة التي تؤدي إلى تورم في الوجه أو الحلق، طفح جلدي خطير، بعض الإضطرابات التي تؤثر على تدفق الدم إلي العينين، وعدم انتظام ضربات القلب، والذبحة الصدرية، والموت القلبي المفاجئ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الإبلاغ عن أعراض جانبية مثل الدوخة بشكل متكرر أكثر في الرجال فوق 75 سنة من العمر مع تناول <strong>سنافي</strong>. تم الإبلاغ عن الإسهال بشكل أكثر تكراراً لدى الرجال البالغين أكثر من 65 سنة من العمر مع تناول <strong>سنافي</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا ظهرت عليك أي أعراض جانبية، قم بالتحدث مع طبيبك أو الصيدلي أو الممرضة. ويشمل ذلك أي أعراض جانبية محتملة غير المُدرجة في هذه النشرة. يمكنك أيضا الإبلاغ عن الأعراض الجانبية مباشرة عبر المركز الوطني للتيقظ والسلامة الدوائية. يمكنك من خلال الإبلاغ عن الأعراض الجانبية أن تساعد في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ بعيداً عن متناول ونظر الأطفال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول سنافي بعد تاريخ انتهاء الصلاحية المدون على العبوة والشريط. بعد &quot;EXP&quot; وتاريخ الانتهاء يشير إلى آخر يوم في هذا الشهر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في العبوة الأصلية لحمايته من الرطوبة. ولا يحفظ في درجة حرارة أعلى من 30 درجة مئوية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي عدم التخلص من الأدوية عن طريق مياه الصرف أو قمامة المنزل. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. فهذه الإجراءات ستساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المادة الفعالة</strong> هي: تادالافيل.</p><p dir="RTL">يحتوي كل قرص مغلفة بطبقة رقيقة من <strong>سنافي </strong>20 ملجم على 20 ملجم من تادالافيل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المكونات الأخرى</strong> هي:</p><p dir="RTL">لاكتوز إن إف سريع التدفق 35957 وأفيسيل بي إتش 101 وكروسكارميللوز صوديوم فئة أ وشيفسيل 60hd3 وصوديوم لورايل سالفات.</p><p dir="RTL">المادة الحبيبية الإضافية:</p><p dir="RTL">أفسيل بى إتش 102 وكروسكارميللوز صوديوم فئة أ وثنائي أوكسيد السيليكون الغروي وستياريت الماغنسيوم.</p><p dir="RTL">المادة المغلفة:</p><p dir="RTL">أوبادري II 32F220050 أصفر وماء منقي بى بى.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قرص <strong>سنافي </strong>20 ملجم هو قرص أصفر اللون، لوزي الشكل، محدب الوجهين، مغلف بطبقة رقيقة، محفور علي أحد الجانبين بـ &quot;T20&quot; والجانب الأخر خال من العلامات.</p><p dir="RTL">تحتوي كل عبوة من <strong>سنافي </strong>20 ملجم على 2 أو 4 أو 6 أو 12 قرص مغلف بطبقة رقيقة.</p><p dir="RTL">قد لا يتم تسويق كل أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الدوائية</strong></p><p dir="RTL">مصنع الأدوية بالقصيم</p><p dir="RTL">المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            سبتمبر 2022.                                            
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SNAFI 20 mg film-coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 20 mg tablet contains 20 mg tadalafil.
Excipient(s) with known effect: Each coated tablet contains 176 mg of lactose.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet).
The 20 mg tablets are yellow-colored, almond-shaped, biconvex, film-coated tablets, engraved with “T20” on one side and plain on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of erectile dysfunction in adult males.</p><p>In order for tadalafil to be effective for the treatment of erectile dysfunction, sexual stimulation is required.</p><p>SNAFI is not indicated for use by women.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><u>&nbsp;</u></p><p><em>Erectile dysfunction in adult Men</em></p><p>In general, the recommended dose is 10 mg taken prior to anticipated sexual activity and with or without food. In those patients in whom tadalafil 10 mg does not produce an adequate effect, 20 mg might be tried. It may be taken at least 30 minutes prior to sexual activity.</p><p>The maximum dose frequency is once per day.</p><p>Tadalafil 10 mg and 20 mg is intended for use prior to anticipated sexual activity and it is not recommended for continuous daily use.</p><p><em>&nbsp;</em></p><p>In patients who anticipate a frequent use of tadalafil (i.e., at least twice weekly) a once daily regimen with the lowest doses of tadalafil might be considered suitable, based on patient choice and the physician&#39;s judgement.</p><p>In these patients, the recommended dose is 5 mg taken once a day at approximately the same time of day. The dose may be decreased to 2.5 mg once a day based on individual tolerability.</p><p>The appropriateness of continued use of the daily regimen should be reassessed periodically.</p><p><em>&nbsp;</em></p><p><u>Special Populations</u></p><p>&nbsp;</p><p><em>Elderly Men</em></p><p>Dose adjustments are not required in elderly patients.</p><p>&nbsp;</p><p><em>Men with Renal Impairment</em></p><p>Dose adjustments are not required in patients with mild to moderate renal impairment. For patients with severe renal impairment, 10 mg is the maximum recommended dose. Once-a-day dosing of 2.5 or 5 mg tadalafil both for the treatment of erectile dysfunction or benign prostatic hyperplasia is not recommended in patients with severe renal impairment. (See sections 4.4 and 5.2.).</p><p>&nbsp;</p><p><em>Men with Hepatic Impairment</em></p><p>For the treatment of erectile dysfunction using on-demand SNAFI the recommended dose of SNAFI is 10 mg taken prior to anticipated sexual activity and with or without food. There is limited clinical data on the safety of SNAFI in patients with severe hepatic impairment (Child-Pugh class C); if prescribed, a careful individual benefit/risk evaluation should be undertaken by the prescribing physician. There are no available data about the administration of doses higher than 10 mg of tadalafil to patients with hepatic impairment. Once-a-day dosing of SNAFI both for the treatment of erectile dysfunction and benign prostatic hyperplasia has not been evaluated in patients with hepatic impairment; therefore, if prescribed, a careful individual benefit/risk evaluation should be undertaken by the prescribing physician. (See sections 4.4 and 5.2.)</p><p>&nbsp;</p><p><em>Men with Diabetes</em></p><p>Dose adjustments are not required in diabetic patients.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>There is no relevant use of SNAFI in the paediatric population with regard to the treatment of erectile dysfunction.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>SNAFI is available as 20 mg film-coated tablets for oral use.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
In clinical studies, tadalafil was shown to augment the hypotensive effects of nitrates. This is thought to result from the combined effects of nitrates and tadalafil on the nitric oxide/cGMP pathway. Therefore, administration of SNAFI to patients who are using any form of organic nitrate is contraindicated. (See section 4.5.)
SNAFI, must not be used in men with cardiac disease for whom sexual activity is inadvisable. Physicians should consider the potential cardiac risk of sexual activity in patients with pre-existing cardiovascular disease.
The following groups of patients with cardiovascular disease were not included in clinical trials and the use of tadalafil is therefore contraindicated:
•	Patients with myocardial infarction within the last 90 days.
•	Patients with unstable angina or angina occurring during sexual intercourse.
•	Patients with New York Heart Association class 2 or greater heart failure in the last 6 months.
•	Patients with uncontrolled arrhythmias, hypotension (<90/50 mmHg), or uncontrolled hypertension.
•	Patients with a stroke within the last 6 months.
SNAFI is contraindicated in patients who have loss of vision in one eye because of non-arteritic anterior ischaemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure (see section 4.4).

The co-administration of PDE5 inhibitors, including tadalafil, with guanylate cyclase stimulators, such as riociguat, is contraindicated as it may potentially lead to symptomatic hypotension (see section 4.5).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Before treatment with SNAFI</u></p><p>A medical history and physical examination should be undertaken to diagnose erectile dysfunction and determine potential underlying causes, before pharmacological treatment is considered.</p><p>Prior to initiating any treatment for erectile dysfunction, physicians should consider the cardiovascular status of their patients, since there is a degree of cardiac risk associated with sexual activity. Tadalafil has vasodilator properties, resulting in mild and transient decreases in blood pressure (see section 5.1), and as such potentiates the hypotensive effect of nitrates (see section 4.3).</p><p>The evaluation of erectile dysfunction should include a determination of potential underlying causes and the identification of appropriate treatment following an appropriate medical assessment. It is not known if SNAFI is effective in patients who have undergone pelvic surgery or radical non-nerve-sparing prostatectomy.</p><p><em>&nbsp;</em></p><p><u>Cardiovascular</u></p><p>Serious cardiovascular events, including myocardial infarction, sudden cardiac death, unstable angina pectoris, ventricular arrhythmia, stroke, transient ischaemic attacks, chest pain, palpitations, and tachycardia, have been reported either post marketing and/or in clinical trials. Most of the patients in whom these events have been reported had pre-existing cardiovascular risk factors. However, it is not possible to definitively determine whether these events are related directly to these risk factors, to SNAFI, to sexual activity, or to a combination of these or other factors.</p><p>&nbsp;</p><p>In patients who are taking alpha<sub>1</sub>&nbsp;blockers, concomitant administration of SNAFI may lead to symptomatic hypotension in some patients (see section 4.5). The combination of tadalafil and doxazosin is not recommended.</p><p>&nbsp;</p><p><u>Vision</u></p><p>Visual defects and cases of NAION have been reported in connection with the intake of tadalafil and other PDE5 inhibitors. Analyses of observational data suggest an increased risk of acute NAION in men with erectile dysfunction following exposure to tadalafil or other PDE5 inhibitors. As this may be relevant for all patients exposed to tadalafil, the patient should be advised that in case of sudden visual defect, he should stop taking Tadalafil and consult a physician immediately (see section 4.3).</p><p>&nbsp;</p><p><u>Decreased or sudden hearing loss</u></p><p>Cases of sudden hearing loss have been reported after the use of tadalafil. Although other risk factors were present in some cases (such as age, diabetes, hypertension and previous hearing loss history) patients should be advised to stop taking tadalafil and seek prompt medical attention in the event of sudden decrease or loss of hearing.</p><p>&nbsp;</p><p><u>Renal and hepatic impairment</u></p><p>Due to increased tadalafil exposure (AUC), limited clinical experience and the lack of ability to influence clearance by dialysis, once-a-day dosing of Tadalafil is not recommended in patients with severe renal impairment.</p><p>There is limited clinical data on the safety of single-dose administration of tadalafil in patients with severe hepatic insufficiency (Child-Pugh class C). Once-a-day administration has not been evaluated in patients with hepatic insufficiency. If SNAFI is prescribed, a careful individual benefit/risk evaluation should be undertaken by the prescribing physician.</p><p><u>Hepatic impairment (tadalafil 10 mg and 20 mg) </u></p><p>There is limited clinical data on the safety of single-dose administration of SNAFI in patients with severe hepatic insufficiency (Child-Pugh Class C). If SNAFI is prescribed, a careful individual benefit/risk evaluation should be undertaken by the prescribing physician.</p><p><em>&nbsp;</em></p><p><u>Priapism and anatomical deformation of the penis</u></p><p>Patients who experience erections lasting 4 hours or more should be instructed to seek immediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency may result.</p><p>SNAFI, should be used with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie&#39;s disease) or in patients who have conditions which may predispose them to priapism (such as sickle cell anaemia, multiple myeloma, or leukaemia).</p><p>&nbsp;</p><p><u>Use with CYP3A4 inhibitors</u></p><p>Caution should be exercised when prescribing SNAFI to patients using potent CYP3A4 inhibitors (ritonavir, saquinavir, ketoconazole, itraconazole, and erythromycin), as increased tadalafil exposure (AUC) has been observed if the medicinal products are combined (see section 4.5).</p><p>&nbsp;</p><p><u>SNAFI and other treatments for erectile dysfunction</u></p><p>The safety and efficacy of combinations of SNAFI and other PDE5 inhibitors or other treatments for erectile dysfunction have not been studied. The patients should be informed not to take SNAFI in such combinations.</p><p><u>&nbsp;</u></p><p><u>Lactose</u></p><p>SNAFI contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies were conducted with 10 mg and/or 20 mg tadalafil, as indicated below. With regard to those interaction studies where only the 10 mg tadalafil dose was used, clinically relevant interactions at higher doses cannot be completely ruled out.</p><p><u>&nbsp;</u></p><p><u>Effects of Other Substances on Tadalafil</u></p><p><u>&nbsp;</u></p><p><em>Cytochrome P450 inhibitors</em></p><p>Tadalafil is principally metabolised by CYP3A4. A selective inhibitor of CYP3A4, ketoconazole (200 mg daily), increased tadalafil (10 mg) exposure (AUC) 2-fold and C<sub>max</sub>&nbsp;by 15 %, relative to the AUC and C<sub>max</sub>&nbsp;values for tadalafil alone. Ketoconazole (400 mg daily) increased tadalafil (20 mg) exposure (AUC) 4-fold and C<sub>max</sub>&nbsp;by 22 %. Ritonavir, a protease inhibitor (200 mg twice daily), which is an inhibitor of CYP3A4, CYP2C9, CYP2C19, and CYP2D6, increased tadalafil (20 mg) exposure (AUC) 2-fold with no change in C<sub>max</sub>. Although specific interactions have not been studied, other protease inhibitors, such as saquinavir, and other CYP3A4 inhibitors, such as erythromycin, clarithromycin, itraconazole, and grapefruit juice, should be co-administered with caution, as they would be expected to increase plasma concentrations of tadalafil (see section 4.4).</p><p>Consequently, the incidence of the adverse reactions listed in section 4.8 might be increased.</p><p><em>Transporters</em></p><p>The role of transporters (for example, p-glycoprotein) in the disposition of tadalafil is not known. Therefore, there is the potential of drug interactions mediated by inhibition of transporters.</p><p><em>Cytochrome P450 inducers</em></p><p>A CYP3A4 inducer, rifampicin, reduced tadalafil AUC by 88%, relative to the AUC values for tadalafil alone (10mg). This reduced exposure can be anticipated to decrease the efficacy of tadalafil; the magnitude of decreased efficacy is unknown. Other inducers of CYP3A4, such as phenobarbital, phenytoin, and carbamazepine, may also decrease plasma concentrations of tadalafil.</p><p>&nbsp;</p><p><u>Effects of Tadalafil on Other Medicinal Products</u></p><p><u>&nbsp;</u></p><p><em>Nitrates</em></p><p>In clinical studies, tadalafil (5 mg, 10 mg and 20 mg) was shown to augment the hypotensive effects of nitrates. Therefore, administration of SNAFI to patients who are using any form of organic nitrate is contraindicated (see section 4.3). Based on the results of a clinical study in which 150 subjects received daily doses of tadalafil 20 mg for 7 days and 0.4 mg sublingual nitroglycerin at various times, this interaction lasted for more than 24 hours and was no longer detectable when 48 hours had elapsed after the last tadalafil dose. Thus, in a patient prescribed any dose of tadalafil (2.5 mg &ndash; 20 mg), where nitrate administration is deemed medically necessary in a life-threatening situation, at least 48 hours should have elapsed after the last dose of SNAFI before nitrate administration is considered. In such circumstances, nitrates should only be administered under close medical supervision with appropriate haemodynamic monitoring.</p><p>&nbsp;</p><p><em>Anti-hypertensives (including calcium channel blockers)</em></p><p>The co-administration of doxazosin (4 and 8 mg daily) and tadalafil (5 mg daily dose and 20 mg as a single dose) increases the blood pressure-lowering effect of this alpha-blocker in a significant manner. This effect lasts at least twelve hours and may be symptomatic, including syncope. Therefore, this combination is not recommended (see section 4.4).</p><p>In interaction studies performed in a limited number of healthy volunteers, these effects were not reported with alfuzosin or tamsulosin. However, caution should be exercised when using tadalafil in patients treated with any alpha-blockers, and notably in the elderly. Treatments should be initiated at minimal dosage and progressively adjusted.</p><p>In clinical pharmacology studies, the potential for tadalafil to augment the hypotensive effects of antihypertensive medicinal products was examined. Major classes of antihypertensive medicinal products were studied, including calcium-channel blockers (amlodipine), angiotensin converting enzyme (ACE) inhibitors (enalapril), beta-adrenergic receptor blockers (metoprolol), thiazide diuretics (bendrofluazide), and angiotensin II receptor blockers (various types and doses, alone or in combination with thiazides, calcium-channel blockers, beta-blockers, and/or alpha-blockers). Tadalafil (10 mg, except for studies with angiotensin II receptor blockers and amlodipine in which a 20 mg dose was applied) had no clinically significant interaction with any of these classes. In another clinical pharmacology study, tadalafil (20 mg) was studied in combination with up to 4 classes of antihypertensives. In subjects taking multiple antihypertensives, the ambulatory-blood-pressure changes appeared to relate to the degree of blood pressure control. In this regard, study subjects whose blood pressure was well controlled, the reduction was minimal and similar to that seen in healthy subjects. In study subjects whose blood pressure was not controlled, the reduction was greater, although this reduction was not associated with hypotensive symptoms in the majority of subjects. In patients receiving concomitant antihypertensive medicinal products, tadalafil 20 mg may induce a blood pressure decrease, which (with the exception of alpha-blockers - see above) is, in general, minor and not likely to be clinically relevant. Analysis of Phase 3 clinical trial data showed no difference in adverse events in patients taking tadalafil with or without antihypertensive medicinal products. However, appropriate clinical advice should be given to patients regarding a possible decrease in blood pressure when they are treated with antihypertensive medicinal products.</p><p>&nbsp;</p><p><em>Riociguat</em></p><p>Preclinical studies showed an additive systemic blood pressure lowering effect when PDE5 inhibitors were combined with riociguat. In clinical studies, riociguat has been shown to augment the hypotensive effects of PDE5 inhibitors. There was no evidence of favourable clinical effect of the combination in the population studied. Concomitant use of riociguat with PDE5 inhibitors, including tadalafil, is contraindicated (see section 4.3).</p><p><em>5-alpha reductase inhibitors</em></p><p>In a clinical trial that compared tadalafil 5 mg co-administered with finasteride 5 mg to placebo plus finasteride 5 mg in the relief of BPH symptoms, no new adverse reactions were identified. However, as a formal drug-drug interaction study evaluating the effects of tadalafil and 5-alpha reductase inhibitors (5-ARIs) has not been performed, caution should be exercised when tadalafil is co-administered with 5-ARIs.</p><p><em>CYP1A2 substrates (e.g., theophylline)</em></p><p>When tadalafil 10 mg was administered with theophylline (a non-selective phosphodiesterase inhibitor) in a clinical pharmacology study, there was no pharmacokinetic interaction. The only pharmacodynamic effect was a small (3.5 bpm) increase in heart rate. Although this effect is minor and was of no clinical significance in this study, it should be considered when co-administering these medicinal products.</p><p><em>Ethinylestradiol and terbutaline </em></p><p>Tadalafil has been demonstrated to produce an increase in the oral bioavailability of ethinylestradiol; a similar increase may be expected with oral administration of terbutaline, although the clinical consequence of this is uncertain.</p><p>&nbsp;</p><p><em>Alcohol</em></p><p>Alcohol concentrations (mean maximum blood concentration 0.08%) were not affected by co-administration with tadalafil (10 mg or 20 mg). In addition, no changes in tadalafil concentrations were seen 3 hours after co-administration with alcohol. Alcohol was administered in a manner to maximize the rate of alcohol absorption (overnight fast with no food until 2 hours after alcohol). Tadalafil (20 mg) did not augment the mean blood pressure decrease produced by alcohol (0.7g/kg or approximately 180 ml of 40% alcohol [vodka] in an 80 kg male) but, in some subjects, postural dizziness and orthostatic hypotension were observed. When tadalafil was administered with lower doses of alcohol (0.6g/kg), hypotension was not observed, and dizziness occurred with similar frequency to alcohol alone. The effect of alcohol on cognitive function was not augmented by tadalafil (10 mg).</p><p>&nbsp;</p><p><em>Cytochrome P450 metabolized medicinal products</em></p><p>Tadalafil is not expected to cause clinically significant inhibition or induction of the clearance of medicinal products metabolized by CYP450 isoforms. Studies have confirmed that tadalafil does not inhibit or induce CYP450 isoforms, including CYP3A4, CYP1A2, CYP2D6, CYP2E1, CYP2C9 and CYP2C19.</p><p>&nbsp;</p><p><em>CYP2C9 substrates (e.g., R-warfarin)</em></p><p>Tadalafil (10 mg and 20 mg) had no clinically significant effect on exposure (AUC) to S-warfarin or R-warfarin (CYP2C9 substrate), nor did tadalafil affect changes in prothrombin time induced by warfarin.</p><p>&nbsp;</p><p><em>Aspirin</em></p><p>Tadalafil (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by acetylsalicylic acid.</p><p>&nbsp;</p><p><em>Antidiabetic medicinal products</em></p><p>Specific interaction studies with antidiabetic medicinal products were not conducted.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>SNAFI is not indicated for use by women.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>There are limited data from the use of tadalafil in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy<strong><em>,&nbsp;</em></strong>embryonal/foetal development, parturition, or postnatal development (see section 5.3). As a precautionary measure, it is preferable to avoid the use of SNAFI during pregnancy.</p><p>&nbsp;</p><p><u>Breastfeeding</u></p><p>Available pharmacodynamic/toxicological data in animals have shown excretion of tadalafil in milk. A risk to the suckling child cannot be excluded. SNAFI should not be used during breast feeding.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Effects were seen in dogs that might indicate impairment of fertility. Two subsequent clinical studies suggest that this effect is unlikely in humans, although a decrease in sperm concentration was seen in some men (see sections 5.1 and 5.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>SNAFI has negligible influence on the ability to drive or use machines. Although the frequency of reports of dizziness in placebo and tadalafil arms in clinical trials was similar, patients should be aware of how they react to SNAFI before driving or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile </u></p><p>The most commonly reported adverse reactions in patients taking tadalafil for the treatment of erectile dysfunction or benign prostatic hyperplasia were headache, dyspepsia, back pain and myalgia, in which the incidences increase with increasing dose of tadalafil. The adverse reactions reported were transient, and generally mild or moderate. The majority of headaches reported with tadalafil once-a-day dosing are experienced within the first 10 to 30 days of starting treatment.</p><p><u>Tabulated summary of adverse reactions</u></p><p>The table below lists the adverse reactions observed from spontaneous reporting and in placebo-controlled clinical trials (comprising a total of 8022 patients on tadalafil and 4422 patients on placebo) for on-demand and once-a-day treatment of erectile dysfunction and the once-a-day treatment of benign prostatic hyperplasia.</p><p>Frequency convention: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000) and very rare (&lt;1/10,000) and not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Immune system disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hypersensitivity reactions</p></td><td style="vertical-align:top"><p>Angioedema<sup>2</sup></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Nervous system disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Stroke<sup>1&nbsp;</sup>(including haemorrhagic events), Syncope, Transient ischaemic attacks<sup>1</sup>, Migraine<sup>2</sup>, Seizures<sup>2</sup>, Transient amnesia</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Eye disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Blurred vision, Sensations described as eye pain</p></td><td style="vertical-align:top"><p>Visual field defect, Swelling of eyelids, Conjunctival hyperaemia, Non-arteritic anterior ischaemic optic neuropathy (NAION)<sup>2</sup>, Retinal vascular occlusion<sup>2</sup></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Ear and labyrinth disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Tinnitus</p></td><td style="vertical-align:top"><p>Sudden hearing loss</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Cardiac disorders<sup>1</sup></em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Tachycardia, Palpitations</p></td><td style="vertical-align:top"><p>Myocardial infarction, Unstable angina pectoris<sup>2</sup>, Ventricular arrhythmia<sup>2</sup></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Vascular disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Flushing</p></td><td style="vertical-align:top"><p>Hypotension<sup>3</sup>, Hypertension</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Respiratory, thoracic and mediastinal disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Nasal congestion</p></td><td style="vertical-align:top"><p>Dyspnoea, Epistaxis</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Gastrointestinal disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Dyspepsia</p></td><td style="vertical-align:top"><p>Abdominal pain, Vomiting, Nausea, Gastro-oesophageal reflux</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Skin and subcutaneous tissue disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Urticaria, Stevens-Johnson syndrome<sup>2</sup>, Exfoliative dermatitis<sup>2</sup>, Hyperhydrosis (sweating)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Musculoskeletal and connective tissue</em> <em>and bone &nbsp;disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Back pain, Myalgia, Pain in extremity</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Renal and urinary disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Haematuria</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Reproductive system and breast disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Prolonged erections</p></td><td style="vertical-align:top"><p>Priapism, Penile haemorrhage, Haematospermia</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>General disorders and administration site conditions</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Chest pain<sup>1</sup>, Peripheral oedema, Fatigue</p></td><td style="vertical-align:top"><p>Facial oedema<sup>2</sup>, Sudden cardiac death<sup>1,2</sup></p></td></tr></tbody></table><p>&nbsp;</p><p><sup>1</sup>&nbsp;Most of the patients had pre-existing cardiovascular risk factors (see section 4.4).</p><p><sup>2</sup>&nbsp;Post marketing surveillance reported adverse reactions not observed in placebo-controlled clinical trials.</p><p><sup>3</sup>&nbsp;More commonly reported when tadalafil is given to patients who are already taking antihypertensive medicinal products.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>A slightly higher incidence of ECG abnormalities, primarily sinus bradycardia, has been reported in patients treated with tadalafil once a day as compared with placebo. Most of these ECG abnormalities were not associated with adverse reactions.</p><p><u>Other special populations</u></p><p>Data in patients over 65 years of age receiving tadalafil in clinical trials, either for the treatment of erectile dysfunction or the treatment of benign prostatic hyperplasia, are limited. In clinical trials with tadalafil taken on demand for the treatment of erectile dysfunction, diarrhoea was reported more frequently in patients over 65 years of age. In clinical trials with tadalafil 5 mg taken once a day for the treatment of benign prostatic hyperplasia, dizziness and diarrhoea were reported more frequently in patients over 75 years of age.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p><strong>To report any side effect(s):</strong></p><p><strong>For Saudi Arabia:</strong></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>Fax: +966-11-205-7662</p><p>Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p>Reporting hotline: 19999.</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p><strong>For UAE:</strong></p><p>Pharmacovigilance &amp; Medical Device section<br />P.O. Box: 1853&nbsp;</p><p>Tel: 80011111</p><p>Email:&nbsp;pv@mohap.gov.ae</p><p>Drug Department<br />Ministry of Health &amp; Prevention,</p><p>Dubai</p><p>UAE</p><p><strong>For OMAN</strong>:</p><p>Department of Pharmacovigilance &amp; Drug Information&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Directorate General of Pharmaceutical Affairs &amp; Drug Control&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Ministry of Health, Sultanate of Oman&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;Phone Nos. 22357687 / 22357686&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</p><p>&nbsp;Fax: 22358489&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Email: dg-padc@moh.gov.om&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Website:&nbsp;www.moh.gov.om</p></td></tr></tbody></table></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single doses of up to 500 mg have been given to healthy subjects, and multiple daily doses up to 100 mg have been given to patients. Adverse events were similar to those seen at lower doses.</p><p>In cases of overdose, standard supportive measures should be adopted, as required. Haemodialysis contributes negligibly to tadalafil elimination.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group<em>:</em>&nbsp;Urologicals, Drugs used in erectile dysfunction.&nbsp;<em>ATC code:</em>&nbsp;G04BE08.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Tadalafil is a selective, reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). When sexual stimulation causes the local release of nitric oxide, inhibition of PDE5 by tadalafil produces increased levels of cGMP in the corpus cavernosum. This results in smooth muscle relaxation and inflow of blood into the penile tissues, thereby producing an erection. Tadalafil has no effect in the treatment of erectile dysfunction in the absence of sexual stimulation.</p><p>The effect of PDE5 inhibition on cGMP concentration in the corpus cavernosum is also observed in the smooth muscle of the prostate, the bladder and their vascular supply. The resulting vascular relaxation increases blood perfusion which may be the mechanism by which symptoms of benign prostatic hyperplasia are reduced. These vascular effects may be complemented by inhibition of bladder afferent nerve activity and smooth muscle relaxation of the prostate and bladder.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>Studies&nbsp;<em>in vitro</em>&nbsp;have shown that tadalafil is a selective inhibitor of PDE5. PDE5 is an enzyme found in corpus cavernosum smooth muscle, vascular and visceral smooth muscle, skeletal muscle, platelets, kidney, lung, and cerebellum. The effect of tadalafil is more potent on PDE5 than on other phosphodiesterases. Tadalafil is &gt;10,000-fold more potent for PDE5 than for PDE1, PDE2, and PDE4, enzymes which are found in the heart, brain, blood vessels, liver, and other organs. Tadalafil is &gt;10,000-fold more potent for PDE5 than for PDE3, an enzyme found in the heart and blood vessels. This selectivity for PDE5 over PDE3 is important because PDE3 is an enzyme involved in cardiac contractility. Additionally, tadalafil is approximately 700-fold more potent for PDE5 than for PDE6, an enzyme which is found in the retina and is responsible for phototransduction. Tadalafil is also &gt;10,000-fold more potent for PDE5 than for PDE7 through PDE10.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>Tadalafil administered to healthy subjects produced no significant difference compared to placebo in supine systolic and diastolic blood pressure (mean maximal decrease of 1.6/0.8 mmHg, respectively), in standing systolic and diastolic blood pressure (mean maximal decrease of 0.2/4.6 mmHg, respectively), and no significant change in heart rate.</p><p>In a study to assess the effects of tadalafil on vision, no impairment of colour discrimination (blue/green) was detected using the Farnsworth-Munsell 100-hue test. This finding is consistent with the low affinity of tadalafil for PDE6 compared to PDE5. Across all clinical studies, reports of changes in colour vision were rare (&lt;0.1%).</p><p>Three studies were conducted in men to assess the potential effect on spermatogenesis of SNAFI 10 mg (one 6-month study) and 20 mg (one 6-month and one 9-month study) administered daily. In two of these studies decreases were observed in sperm count and concentration related to tadalafil treatment of unlikely clinical relevance. These effects were not associated with changes in other parameters, such as motility, morphology, and FSH.</p><p>&nbsp;</p><p><em>Erectile dysfunction</em></p><p>Three clinical studies were conducted in 1054 patients in an at-home setting to define the period of responsiveness to SNAFI on demand. Tadalafil demonstrated statistically significant improvement in erectile function and the ability to have successful sexual intercourse up to 36 hours following dosing, as well as patients&#39; ability to attain and maintain erections for successful intercourse compared to placebo as early as 16 minutes following dosing.</p><p>In a 12-week study performed in 186 patients (142 tadalafil, 44 placebo) with erectile dysfunction secondary to spinal cord injury, tadalafil significantly improved the erectile function leading to a mean per-subject proportion of successful attempts in patients treated with tadalafil 10 or 20 mg (flexible-dose, on demand) of 48% as compared to 17% with placebo.</p><p>Tadalafil at doses of 2 to 100 mg has been evaluated in 16 clinical studies involving 3250 patients, including patients with erectile dysfunction of various severities (mild, moderate, severe), etiologies, ages (range 21-86 years), and ethnicities. Most patients reported erectile dysfunction of at least 1 year in duration. In the primary efficacy studies of general populations, 81% of patients reported that SNAFI improved their erections as compared to 35% with placebo. Also, patients with erectile dysfunction in all severity categories reported improved erections whilst taking SNAFI (86%, 83%, and 72% for mild, moderate, and severe, respectively, as compared to 45%, 42%, and 19% with placebo). In the primary efficacy studies, 75% of intercourse attempts were successful in SNAFI-treated patients as compared to 32% with placebo.</p><p>For once-a-day evaluation of tadalafil at doses of 2.5, 5, and 10 mg 3 clinical studies were initially conducted involving 853 patients of various ages (range 21-82 years) and ethnicities, with erectile dysfunction of various severities (mild, moderate, severe) and etiologies. In the two primary efficacy studies of general populations, the mean per-subject proportion of successful intercourse attempts were 57 and 67% on tadalafil 5 mg, 50% on tadalafil 2.5 mg as compared to 31 and 37% with placebo. In the study in patients with erectile dysfunction secondary to diabetes, the mean per-subject proportion of successful attempts were 41 and 46% on tadalafil 5 mg and 2.5 mg, respectively, as compared to 28% with placebo. Most patients in these three studies were responders to previous on-demand treatment with PDE5 inhibitors. In a subsequent study, 217 patients who were treatment-naive to PDE5 inhibitors were randomised to SNAFI 5 mg once a day vs. placebo. The mean per-subject proportion of successful sexual intercourse attempts was 68% for SNAFI patients compared to 52% for patients on placebo.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&ldquo;A single study has been performed in paediatric patients with Duchenne Muscular Dystrophy (DMD) in which no evidence of efficacy was seen. The randomised, double-blind, placebo-controlled, parallel, 3-arm study of tadalafil was conducted in 331 boys aged 7-14 years with DMD receiving concurrent corticosteroid therapy. The study included a 48-week double-blind period where patients were randomised to tadalafil 0.3 mg/kg, tadalafil 0.6 mg/kg, or placebo daily. Tadalafil did not show efficacy in slowing the decline in ambulation as measured by the primary 6 minute walk distance (6MWD) endpoint: least squares (LS) mean change in 6MWD at 48 weeks was -51.0 meters (m) in the placebo group, compared with -64.7 m in the tadalafil 0.3 mg/kg group (p = 0.307) and -59.1 m in the tadalafil 0.6 mg/kg group (p = 0.538). In addition, there was no evidence of efficacy from any of the secondary analyses performed in this study. The overall safety results from this study were generally consistent with the known safety profile of tadalafil and with adverse events (AEs) expected in a paediatric DMD population receiving corticosteroids&rdquo;.</p><p>The European Medicines Agency has waived the obligation to submit the results of studies in all subsets of the paediatric population in the treatment of the erectile dysfunction. See section 4.2 for information on paediatric use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Tadalafil is readily absorbed after oral administration and the mean maximum observed plasma concentration (C<sub>max</sub>) is achieved at a median time of 2 hours after dosing. Absolute bioavailability of tadalafil following oral dosing has not been determined.</p><p>The rate and extent of absorption of tadalafil are not influenced by food, thus SNAFI may be taken with or without food. The time of dosing (morning versus evening) had no clinically relevant effects on the rate and extent of absorption.</p><p><u>Distribution</u></p><p>The mean volume of distribution is approximately 63 liters, indicating that tadalafil is distributed into tissues. At therapeutic concentrations, 94 % of tadalafil in plasma is bound to proteins. Protein binding is not affected by impaired renal function.</p><p>Less than 0.0005 % of the administered dose appeared in the semen of healthy subjects.</p><p><u>Biotransformation</u></p><p>Tadalafil is predominantly metabolised by the cytochrome P450 (CYP) 3A4 isoform. The major circulating metabolite is the methylcatechol glucuronide. This metabolite is at least 13,000-fold less potent than tadalafil for PDE5. Consequently, it is not expected to be clinically active at observed metabolite concentrations.</p><p><u>Elimination</u></p><p>The mean oral clearance for tadalafil is 2.5 L/h and the mean half-life is 17.5 hours in healthy subjects. Tadalafil is excreted predominantly as inactive metabolites, mainly in the faeces (approximately 61 % of the dose) and to a lesser extent in the urine (approximately 36 % of the dose).</p><p><u>Linearity/Non-Linearity</u></p><p>Tadalafil pharmacokinetics in healthy subjects are linear with respect to time and dose. Over a dose range of 2.5 to 20 mg, exposure (AUC) increases proportionally with dose. Steady-state plasma concentrations are attained within 5 days of once daily dosing.</p><p>Pharmacokinetics determined with a population approach in patients with erectile dysfunction are similar to pharmacokinetics in subjects without erectile dysfunction.</p><p><u>Special Populations</u></p><p><em>Elderly</em></p><p>Healthy elderly subjects (65 years or over) had a lower oral clearance of tadalafil, resulting in 25 % higher exposure (AUC) relative to healthy subjects aged 19 to 45 years. This effect of age is not clinically significant and does not warrant a dose adjustment.</p><p><em>Renal Insufficiency</em></p><p>In clinical pharmacology studies using single dose tadalafil (5 mg to 20 mg), tadalafil exposure (AUC) approximately doubled in subjects with mild (creatinine clearance 51 to 80 mL/min) or moderate (creatinine clearance 31 to 50 mL/min) renal impairment and in subjects with end-stage renal disease on dialysis. In haemodialysis patients, C<sub>max</sub>&nbsp;was 41 % higher than that observed in healthy subjects. Haemodialysis contributes negligibly to tadalafil elimination.</p><p><em>Hepatic Insufficiency</em></p><p>Tadalafil exposure (AUC) in subjects with mild and moderate hepatic impairment (Child-Pugh class A and B) is comparable to exposure in healthy subjects when a dose of 10 mg is administered. There is limited clinical data on the safety of tadalafil in patients with severe hepatic insufficiency (Child-Pugh class C). There are no available data about the administration of once-a-day dosing of tadalafil to patients with hepatic impairment. If tadalafil is prescribed once-a-day, a careful individual benefit/risk evaluation should be undertaken by the prescribing physician. There are no available data about the administration of doses higher than 10 mg of tadalafil to patients with hepatic impairment.</p><p><em>Patients with diabetes</em></p><p>Tadalafil exposure (AUC) in patients with diabetes was approximately 19 % lower than the AUC value for healthy subjects. This difference in exposure does not warrant a dose adjustment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, and toxicity to reproduction.</p><p>There was no evidence of teratogenicity, embryotoxicity, or foetotoxicity in rats or mice that received up to 1000 mg/kg/day tadalafil. In a rat prenatal and postnatal development study, the no observed effect dose was 30 mg/kg/day. In the pregnant rat the AUC for calculated free drug at this dose was approximately 18-times the human AUC at a 20 mg dose.</p><p>There was no impairment of fertility in male and female rats. In dogs given tadalafil daily for 6 to 12 months at doses of 25 mg/kg/day (resulting in at least a 3-fold greater exposure [range 3.7-18.6] than seen in humans given a single 20 mg dose) and above, there was regression of the seminiferous tubular epithelium that resulted in a decrease in spermatogenesis in some dogs. See also section 5.1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The other ingredients are:</p><p>Lactose NF Fast Flow, Avicel PH 101, Croscarmellose sodium type A, Sheffcel 60hd3, and Sodium Lauryl Sulphate.</p><p>Extra Granular Material:</p><p>Avicel PH 102, Croscarmellose sodium type A, Colloidal Silicon Dioxide, and Magnesium Stearate.</p><p>Coating:</p><p>Opadry II 32F220050 Yellow, and Purified Water BP.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.&nbsp;<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of the reach and sight of children.&nbsp;</p><p>​Store in the original package in order to protect from moisture. Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Transparent thermoformed Aclar/PVC&nbsp;blister strips with aluminum foil lid.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p><p>​​Each unit carton contains 2, 4, 6 or 12 film-coated tablets.​​ &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SPIMACO
Al-Qassim Pharmaceutical Plant
Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                September 2022.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>